1. Home
  2. HURA vs EPM Comparison

HURA vs EPM Comparison

Compare HURA & EPM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • HURA
  • EPM
  • Stock Information
  • Founded
  • HURA 2009
  • EPM 2003
  • Country
  • HURA United States
  • EPM United States
  • Employees
  • HURA N/A
  • EPM N/A
  • Industry
  • HURA
  • EPM Oil & Gas Production
  • Sector
  • HURA
  • EPM Energy
  • Exchange
  • HURA Nasdaq
  • EPM Nasdaq
  • Market Cap
  • HURA 145.6M
  • EPM 174.3M
  • IPO Year
  • HURA N/A
  • EPM 1996
  • Fundamental
  • Price
  • HURA $2.37
  • EPM $5.17
  • Analyst Decision
  • HURA Strong Buy
  • EPM Hold
  • Analyst Count
  • HURA 2
  • EPM 1
  • Target Price
  • HURA $11.50
  • EPM $4.50
  • AVG Volume (30 Days)
  • HURA 823.7K
  • EPM 147.8K
  • Earning Date
  • HURA 08-14-2025
  • EPM 09-16-2025
  • Dividend Yield
  • HURA N/A
  • EPM 9.28%
  • EPS Growth
  • HURA N/A
  • EPM N/A
  • EPS
  • HURA N/A
  • EPM N/A
  • Revenue
  • HURA N/A
  • EPM $85,959,000.00
  • Revenue This Year
  • HURA N/A
  • EPM $0.85
  • Revenue Next Year
  • HURA N/A
  • EPM $0.56
  • P/E Ratio
  • HURA N/A
  • EPM N/A
  • Revenue Growth
  • HURA N/A
  • EPM 3.79
  • 52 Week Low
  • HURA $1.80
  • EPM $4.05
  • 52 Week High
  • HURA $8.40
  • EPM $6.14
  • Technical
  • Relative Strength Index (RSI)
  • HURA 38.05
  • EPM 57.97
  • Support Level
  • HURA $2.43
  • EPM $4.96
  • Resistance Level
  • HURA $2.65
  • EPM $5.23
  • Average True Range (ATR)
  • HURA 0.18
  • EPM 0.10
  • MACD
  • HURA -0.07
  • EPM 0.00
  • Stochastic Oscillator
  • HURA 5.39
  • EPM 81.92

About HURA TuHURA Biosciences Inc. Common Stock

TuHURA Biosciences Inc is a Phase 3 registration stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. It is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda (pembrolizumab) in first-line treatment for advanced or metastatic Merkel Cell Carcinoma.

About EPM Evolution Petroleum Corporation Inc.

Evolution Petroleum Corp is an independent oil and gas company operating in the United States. It is engaged predominantly in the acquisition, exploitation, and development of properties for the production of crude oil and natural gas, onshore in the United States. The company's revenues are generated from its crude oil, natural gas, and NGL production from the Jonah Field in Sublette County, Wyoming; the Williston Basin in North Dakota; the Barnett Shale located in North Texas; the Hamilton Dome Field in Wyoming; and the Delhi Field in Northeast Louisiana.

Share on Social Networks: